Melanoma, SCCHN research hub

A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy

This study is testing a new treatment, TILT-123 with avelumab, for certain skin cancers (melanoma) and head and neck cancers that haven't responded well to other treatments. It's an early-stage trial looking at safety and finding the right dose.